KORU Medical Systems (NASDAQ:KRMD) and Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis

Vivos Therapeutics (NASDAQ:VVOS) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Vivos Therapeutics and KORU Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-98.42%	-665.17%	-122.48%
KORU Medical Systems	-45.24%	-25.10%	-18.73%

Earnings and Valuation

This table compares Vivos Therapeutics and KORU Medical Systems’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$13.80 million	0.51	-$13.58 million	($11.05)	-0.22
KORU Medical Systems	$28.52 million	3.71	-$13.74 million	($0.28)	-8.25

Vivos Therapeutics has higher earnings, but lower revenue than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vivos Therapeutics has a beta of 8.03, indicating that its share price is 703% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vivos Therapeutics and KORU Medical Systems, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	0	0	0	0	N/A
KORU Medical Systems	0	0	4	0	3.00

KORU Medical Systems has a consensus price target of $3.50, suggesting a potential upside of 51.52%. Given KORU Medical Systems’ higher possible upside, analysts plainly believe KORU Medical Systems is more favorable than Vivos Therapeutics.

Insider & Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 9.6% of Vivos Therapeutics shares are held by insiders. Comparatively, 21.7% of KORU Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

KORU Medical Systems beats Vivos Therapeutics on 10 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About KORU Medical Systems

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.